Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon

Peregrine Ophthalmic

Status and phase: Completed; Phase 1

Conditions: Lower Eyelid Steatoblepharon

Treatments: Drug: Placebo; Drug: POLAT-001

Study type: Interventional

Funder types: Industry

Identifiers

NCT05935527

POLAT-001-CS-402b

Details and patient eligibility

About

This trial is testing a drug to see if multiple injections to the undereye bags of selected patients decreases the volume of the eyebags as compared to placebo. Subjects will be randomized to receive either one of two doses of POLAT-001 or placebo. POLAT-001 will be injected into the eyebags at three of the visits. Each subject will attend 7-10 clinic visits over 98 to 140 days total to assess efficacy and safety.

Full description

This trial is a proof-of-concept trial and is testing a drug to see if multiple injections to the undereye bags of selected patients decreases the volume of the eyebags as compared to placebo. Subjects will be randomized to receive either one of two doses of POLAT-001 (1 mg/mL or 2 mg/mL) or placebo (normal saline). POLAT-001 will be injected into the eyebags at three of the visits. Each subject will attend 7-10 clinic visits total over 98 to 140 days to assess efficacy and safety. Subjects assigned to placebo will crossover to receive active treatment. Efficacy will be determined using questionnaires and photography. Safety will be assessed by subject-reported events and investigator observations of the subjects.

Enrollment: 50 patients

Sex: All

Ages: 22+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adult subjects, 22 years or older with moderate to severe convexity or fullness associated with periorbital fat.
• Subject has moderate to severe eyebags per Goldberg and Simon's Orbital Fat Grading System, per protocol requirements.
• Willing and able to attend all study visits.

Exclusion criteria

• Any signs or symptoms of periorbital disease in the study eye and related complications, as determined by the investigator.
• Active thyroid eye disease, chronic ocular inflammatory orbital disease or other ophthalmic disease that could confound study results.
• Evidence of infection, or clinically significant periocular, periorbital or conjunctival inflammation or conditions that in the opinion of the investigator would constitute a risk or could confound the study results.
• History of hypersensitivity to prostaglandin analogs or prostaglandin PF2alpha treatments.
• Known hypersensitivity to any component of the investigational product formulation.
• Use of periocular corticosteroids within 2 months prior to Screening.
• Use of intravitreal (IVT) injections within 3 weeks prior to Screening in the study eye.
• Surgical or laser treatment of the eye or surrounding anatomical structures within 6 months prior to Screening in the study eye.
• Previous history of lower incisional eyelid surgery.
• Previous history of undereye lid tattoo or underage lash extensions.
• Previous history of infra-orbital or anterior medical cheek fillers within 24 months prior to Screening.
• The subject has received botulinum toxin treatment of the inferior pretarsal orbicularis oculi muscle within 6 months of the first injection.
• History of ocular trauma in the study eye within 6 months prior to Screening.
• Any concurrent disease that would require medical or surgical intervention during the study in the study eye (e.g., retinal detachment, significant cataract, uncontrolled glaucoma).
• Facial nerve injury or abnormal weakness, other facial rejuvenation injections (not including botulinum toxin) in the treated area, facial surgery, or facial trauma within 3 months prior to Screening. History or concurrent systemic condition that would preclude the safe administration of the study treatment or confound the results of the safety (e.g., renal or hepatic impairment).
• Any laboratory findings that based on clinical assessment of the investigator would place the subject at risk or could confound th study results.
• Significant infraorbital vascular prominence.
• Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.
• Participation in an interventional clinical study within 30 days prior to Screening.
• Any other criterion that based on the clinical judgement of the investigator may place the subject at risk or confound study results.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

50 participants in 2 patient groups, including a placebo group

Placebo (Normal Saline)

Placebo Comparator group

Description:

Subjects will be randomized 1:5 (1 Placebo subject to 5 receiving active treatment) to receive placebo (Normal Saline) with a volume of 120 microliters injection.

Treatment:

Drug: Placebo

POLAT-001

Experimental group

Description:

Subjects will be randomized 1:5 (1 Placebo subject to 5 receiving active treatment) to receive POLAT-001 with a volume of 120 microliters injection, at either 1 mg/mL or 2 mg/mL

Treatment:

Drug: POLAT-001